17 results about "Aescin" patented technology

This invention discloses a composition for relieving allergies, itching, and improving rough skin, its preparation method, and its application. The composition comprises the following active ingredients: asiaticoside, centella asiatica extract, kava extract, aescin, allantoin, and sodium hyaluronate. This invention prepares the composition using raw materials and proportions containing asiaticoside, centella asiatica extract, kava extract, aescin, allantoin, and sodium hyaluronate. The synergistic effect between these components results in excellent anti-allergic, anti-itch, and skin-roughening effects. After preparing the composition into a soothing and anti-itch cream, tests showed that it significantly reduced the a* value and lactic acid stinging score of sensitive skin. Doctor evaluation methods further confirmed its significant improvement effects on burning, erythema, swelling, peeling, stinging, and itching of sensitive skin, while also showing a significant effect on improving rough skin.

The invention relates to the technical field of supramolecules, in particular to a ginsenoside CK-aescin supramolecule, in the supramolecule, ginsenoside CK and aescin are formed through a non-covalent bond, the mass ratio of ginsenoside CK to aescin is 1: (1-25), and a preparation method comprises the following steps: dispersing aescin in an organic solvent aqueous solution to prepare a suspension A, dissolving ginsenoside CK in ethanol to prepare a solution D for later use; stirring the suspension A to obtain a suspension B; performing ultrasonic treatment on the suspension B to obtain emulsion C; slowly adding the emulsion C into the solution D while stirring, stirring to obtain a ginsenoside CK-aescin supramolecular solution crude product, and dialyzing. According to the ginsenoside CK-aescin supramolecule prepared by the invention, an IVPT test shows that the transdermal absorption capacity of the ginsenoside CK-aescin supramolecule is remarkably improved, so that the ginsenoside CK-aescin supramolecule can be better absorbed by human skin, and the efficacy of the ginsenoside CK-aescin supramolecule is favorably exerted.

This invention discloses a method for preparing and applying aescin in cosmetics, belonging to the field of plant active ingredient extraction technology. The method for preparing aescin includes the following steps: adding horse chestnut seeds to an organic solvent, then adding an alkaloid, heating and refluxing to extract, and then removing the organic solvent to obtain a crude extract; dissolving the crude extract in water, adding a cyclic oligosaccharide, stirring and reacting, then adding an organic acid, heating and reacting, and finally purifying to obtain aescin. The preparation method of this invention can improve both the extraction rate and retention rate of aescin.

The invention belongs to the technical field of biological medicines, and particularly relates to application of aescin in preparation of a product for inducing autophagy of skin cells. According to the application disclosed by the invention, research finds that aescin can induce autophagy of skin keratinocytes for the first time, and the expression level of autophagy-related proteins LC3-I and LC3-II in the skin keratinocytes can be remarkably improved; in addition, aescin and ursolic acid have a synergistic effect in the aspect of inducing skin keratinocyte autophagy, and are safe and non-irritant to skin. Therefore, the aescin and the composition of the aescin and the ursolic acid can be used for preparing products for inducing autophagy of skin cells so as to resist aging, remove freckles, whiten skin, control oil and strengthen a skin cuticle barrier, and products for slowing down a scleroderma process / relieving a scleroderma symptom, slowing down an atopic dermatitis process / relieving an atopic dermatitis symptom and relieving acne. The traditional Chinese medicine composition has the advantages of remarkable curative effect and high safety.

The invention provides UDP-glucose transferase for catalyzing glycosylation at C2'site of aescin, a gene, a primer group and application, and belongs to the technical field of aescin. The method is based on aesculus chinensis genome and transcriptome data analysis; according to the present invention, the UGT gene for catalyzing the C2'site of the protoaescinogenin-3-O-beta-D-glucopyranuronide is excavated, and the tobacco transient expression system is utilized to verify that the AcUGT94AK1, the AcUGT94AK3 and the AcUGT94AK6 can catalyze the protoaescinogenin-3-O-beta-D-glucopyranuronide to form the protoaescinogenin-3-O-beta-D-glucopyranuronide-(1-> 2)-beta-D-glucoside, such that the UGT gene can be used for catalyzing the C2 'site of the protoaescinogenin-3-O-beta-D-glucopyranuronide; the invention not only provides an important gene element for biosynthesis of aescin compounds, but also provides a key gene locus for molecular breeding of aesculus chinensis, and provides a theoretical basis for glycosylation modification of other triterpenoid saponins.

The invention relates to an application of an NKT-like cell in the onset of primary sicca syndrome. The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating primary sicca syndrome. The invention relates to a pharmaceutical composition for treating primary sicca syndrome. The pharmaceutical composition is prepared from artemisia vulgaris and a total glucosides capsule of radix paeoniae alba. The total glucosides of paeony capsule is combined with iguratimod to treat the primary sicca syndrome, so that the saliva flow rate and tear flow rate of a patient can be effectively improved, the NKT-like cell content is increased, the body immune function is enhanced, the improvement of clinical symptoms is promoted, the clinical treatment effect is remarkably improved, and the total glucosides of paeony capsule is worthy of clinical popularization.

The invention discloses application of ziyuglycoside II in preparation of a medicine for treating and relieving acute promyelocytic leukemia and / or ATRA-resistant acute promyelocytic leukemia and a medicine composition, and belongs to the technical field of medicine. Experiments prove that ziyuglycoside II can inhibit proliferation of acute promyelocytic leukemia cells (NB4) and transretinoic acid (ATRA) drug-resistant acute promyelocytic leukemia cells (NB4-R2), induce differentiation of the NB4 and the NB4-R2, promote apoptosis of the NB4-R2 cells and relieve disease development of ATRA drug-resistant cell xenotransplantation acute promyelocytic leukemia. The ziyuglycoside II is developed as a novel drug for resisting acute promyelocytic leukemia or an auxiliary component thereof, and the ziyuglycoside II has obvious effects of resisting acute promyelocytic leukemia and drug-resistant acute promyelocytic leukemia; the invention provides a new approach and means for treating acute promyelocytic leukemia and drug-resistant acute promyelocytic leukemia.

This invention provides a horse chestnut tiglyl-CoA ligase gene. AcCCL3 This invention relates to the AcCCL3 protein and its applications, belonging to the field of gene technology. For the first time, this invention has identified and verified the key enzyme gene responsible for the biosynthesis of tigrazol-CoA in horse chestnut. AcCCL3 This invention provides a complete analysis of its biosynthetic pathway, filling a knowledge gap in this field. It can be based on... AcCCL3 This gene, through synthetic biology strategies and an engineered system, has achieved the synthesis of tiglyl-CoA, completely eliminating reliance on traditional, complex, and demanding chemical synthesis routes. This significantly reduces production costs from the source, enabling large-scale production and successfully solving the core challenge of large-scale, stable preparation and supply of tiglyl-CoA. It also breaks through the key precursor constraints that have hindered the biosynthetic research, drug development, and industrial production of a series of high-value aescin compounds, represented by aescin A.

The invention belongs to the technical field of application of natural compounds, and particularly relates to novel application of aescin. Aescin is applied to preparation of the atherosclerosis medicine for cardiovascular diseases, reduction of AMPK phosphorylation induces increase of p-mTOR expression, reduction of autophagy causes accumulation of cholesterol in macrophage-derived foam cells, and finally occurrence and development of atherosclerosis are promoted. According to the application, AMPK is activated through aescin, mTOR phosphorylation is reduced to induce autophagy of the macrophage-derived foam cells, ABCA1 protein expression is up-regulated, cholesterol outflow of the macrophage-derived foam cells is promoted, and therefore atherosclerosis is improved.

This invention discloses the application of aescin in the preparation of a feed repellent for fruit flies. This invention is the first to propose that the natural plant medicine aescin can be used as an insect feed repellent. Verification has shown that it has a significant feeding repellent effect on both adult and larval fruit flies, making it suitable as a feed repellent for fruit fly pests. Further development into a natural drug for controlling fruit fly pests is possible. It is non-toxic and pollution-free to various crops, vegetables, fruits, and other economic crops, will not induce drug resistance, and will not pollute the environment or harm human health, demonstrating excellent application prospects.

The invention provides a 4 '-O-glucose glycosyl transferase AcUGT87AZ3 protein in an aesculus chinensis triterpene synthesis pathway, an AcUGT87AZ3 gene and application of the AcUGT87AZ3 protein and the AcUGT87AZ3 gene, and belongs to the technical field of biology. The method is combined with transcriptome data analysis; the UGT gene capable of catalyzing the 4 '-O-glucose glycosylation of 3 beta-O-{beta-D-glucopyranoglucuronic acid}-protoaescin, geligillaceae saponin IC or 21 beta-O-tigillaceae acyl-22 alpha-O-acetyl-geligillaceae saponin IC is obtained through screening, and the UGT gene can be used for catalyzing the 4'-O-glucose glycosylation of the geligillaceae saponin IC. An escherichia coli in-vitro enzyme activity experiment and a tobacco transient expression system verify that the AcUGT87AZ3 can catalyze the synthesis of 3 beta-O-{[beta-D-glucopyranose-(1-4)]-beta-D-glucopyranuronic acid}-proaescin, aescin B and aescin A. The AcUGT87AZ3 can catalyze the synthesis of 3 beta-O-{[beta-D-glucopyranose-(1-4)]-beta-D-glucopyranuronic acid}-proaescin.

The application relates to the technical field of ulcerative colitis prevention and treatment, and particularly relates to application of avicularin in preparation of ulcerative colitis prevention and treatment drugs. Avicularin can effectively improve ulcerative colitis of mice caused by dextran sulfate sodium (DSS), can not only improve colon injury and reduce DAI index, but also can reduce expression of inflammatory cytokines and increase expression of intestinal mucosal barrier related proteins.

The present application relates to the field of medicine, and more particularly to the use of aesculin or verbascoside in the preparation of a medicament for treating and / or preventing IgAN. The present inventors have found that aesculin and / or verbascoside can significantly improve proteinuria caused by IgAN and reduce inflammatory reactions, thereby playing a role in protecting kidney function, and do not have the serious shortcomings of clinically commonly used drugs, indicating that aesculin and / or verbascoside have a strong and low-toxicity effect in treating IgAN. In addition, aesculin and / or verbascoside are a natural compound, low toxicity and easy to be accepted by the human body.

The application belongs to the technical field of biological medicine, and particularly relates to application of aesculin B in preparation of a medicine for preventing and / or treating gouty nephropathy. The aesculin B can reduce a kidney index, reduce contents of serum creatinine, urea nitrogen and uric acid, reduce kidney crystal precipitates and resist renal interstitial fibrosis, so that an effect of preventing and / or treating gouty nephropathy is achieved.

The invention discloses a starch film slow-release patch for promoting wound healing and a preparation method thereof.The method comprises the steps that 1, silymarin, centella asiatica extract, aescin, aloe polysaccharide, lithospermum erythrorhizon extract, olive oil, lecithin and cetostearyl alcohol polyether are taken and mixed to be uniform, phosphatidylinositol and deionized water are added, low-speed stirring and high-speed shearing are conducted in sequence at the temperature of 25-35 DEG C, and the starch film slow-release patch for promoting wound healing is obtained; the microcrystal nano-emulsion is obtained; 2, adding gelatin and starch into deionized water, heating for 5-15 minutes at 60-80 DEG C while stirring, cooling to 40-50 DEG C, adding citric acid, calcium citrate, glycerol, ethylene glycol and the crystal nano-emulsion, and uniformly mixing to obtain mixed paste liquid; 3, the mixed paste liquid is contained in a vacuumizing container, vacuumizing is conducted, and degassed mixed paste liquid is obtained; 4, carrying out roll forming on the mixed paste to obtain a starch film; and 5, cutting the starch film into the starch film slow-release patch. The starch film sustained-release patch prepared by the invention has good flexibility, viscosity and air permeability, and is capable of stopping bleeding, resisting inflammation and promoting wound healing.

The invention provides a C24-site hydroxylase gene CYP7140E67 of stamen eugenin C, a CYP7140E67 protein and application of the C24-site hydroxylase gene CYP7140E67 and belongs to the technical field of genes. According to the invention, the key enzyme for catalyzing hydroxylation of the C24 site of the stamen eugenin C is successfully found and identified, the blank of research on the catalytic enzyme in aesculus chinensis is filled, and a key gene and a protein coding sequence are provided for biosynthetic pathway analysis and synthetic biology research of the original aescin and derivatives thereof. Moreover, the proaescin is heterogeneously synthesized by expressing the CYP714E67 in the Bensi tobacco leaves, a living body biosynthesis system is constructed, the CYP714E67 is heterogeneously expressed by utilizing saccharomyces cerevisiae, and the in-vitro synthesis of the proaescin is realized by virtue of yeast microsomes, so that a flexible path is provided for industrial production; the problem of resource supply of aescin A is solved, and a solid foundation is laid for promoting cultivation of new varieties of high-yield plants and industrial biosynthesis.

This invention relates to the field of pharmaceuticals, and more particularly to the application of honeysuckle glycosides or verbenacin in alleviating and / or delaying renal fibrosis. This invention has discovered that honeysuckle glycosides can significantly inhibit epithelial-mesenchymal transition, thereby protecting renal function. More unexpectedly, it has been found that the combined use of honeysuckle glycosides and verbenacin significantly enhances the anti-fibrotic effect compared to using either alone, exhibiting a synergistic effect without the serious drawbacks of commonly used clinical drugs. While verbenacin itself possesses certain anti-inflammatory and antioxidant activity, under the experimental conditions of this invention, the anti-fibrotic effect of verbenacin alone is weaker than that of honeysuckle glycosides; however, when used in combination with honeysuckle glycosides, the latter's anti-fibrotic effect is significantly enhanced, suggesting a complementary or synergistic molecular mechanism between the two. Therefore, honeysuckle glycosides, used alone or in combination with verbenacin, has a potent and low-toxicity therapeutic effect on renal fibrosis. Furthermore, both honeysuckle glycosides and verbenacin are natural compounds, low in toxicity, and readily accepted by the human body.